{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:36:31Z","timestamp":1793795791830,"version":"4.6.1"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1038\/s41577-021-00547-6","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T06:04:53Z","timestamp":1621231493000},"page":"85-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1097,"title":["Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-1130","authenticated-orcid":false,"given":"Emma C.","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8716-781X","authenticated-orcid":false,"given":"Theodoros","family":"Giavridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"547_CR1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"547_CR2","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).","journal-title":"Sci. Transl. Med."},{"key":"547_CR3","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509\u20131518 (2013). Together with Brentjens et al. (2013), this article reports early clinical data demonstrating the efficacy of CD19CAR T cells in patients with refractory acute lymphoblastic leukaemia.","journal-title":"N. Engl. J. Med."},{"key":"547_CR4","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"547_CR5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540\u2013549 (2015).","journal-title":"J. Clin. Oncol."},{"key":"547_CR6","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).","journal-title":"Sci. Transl. Med."},{"key":"547_CR7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher, J. et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6\/CD28 receptor. Nat. Biotechnol. 20, 70\u201375 (2002). This article is the first demonstration that fusion receptors containing both T cell receptor and CD28 signalling moieties could redirect and amplify human T cell responses.","journal-title":"Nat. Biotechnol."},{"key":"547_CR8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","volume":"18","author":"C Imai","year":"2004","unstructured":"Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 18, 676\u2013684 (2004).","journal-title":"Leukemia."},{"key":"547_CR9","first-page":"188","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"547_CR10","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"547_CR11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"547_CR12","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321\u20133330 (2016).","journal-title":"Blood"},{"key":"547_CR13","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295\u20132306 (2017).","journal-title":"Blood"},{"key":"547_CR14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018). This review discusses clinical aspects of CAR T cell-mediated toxicities.","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"547_CR15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"547_CR16","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov."},{"key":"547_CR17","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958\u2013971 (2018).","journal-title":"Cancer Discov."},{"key":"547_CR18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamaoncol.2019.3869","volume":"6","author":"FL Locke","year":"2019","unstructured":"Locke, F. L., Go, W. Y. & Neelapu, S. S. Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review. JAMA Oncol. 6, 281\u2013290 (2019).","journal-title":"JAMA Oncol."},{"key":"547_CR19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","volume":"9","author":"RJ Brentjens","year":"2003","unstructured":"Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279\u2013286 (2003).","journal-title":"Nat. Med."},{"key":"547_CR20","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","volume":"66","author":"CM Kowolik","year":"2006","unstructured":"Kowolik, C. M. et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66, 10995\u201311004 (2006).","journal-title":"Cancer Res."},{"key":"547_CR21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"547_CR22","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","volume":"4","author":"M Pennisi","year":"2020","unstructured":"Pennisi, M. et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 4, 676\u2013686 (2020).","journal-title":"Blood Adv."},{"key":"547_CR23","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le, R. Q. et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23, 943\u2013947 (2018).","journal-title":"Oncologist"},{"key":"547_CR24","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.4049\/jimmunol.1301523","volume":"191","author":"SJC van der Stegen","year":"2013","unstructured":"van der Stegen, S. J. C. et al. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? J. Immunol. 191, 4589\u20134598 (2013).","journal-title":"J. Immunol."},{"key":"547_CR25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664\u2013679 (2016).","journal-title":"Cancer Discov."},{"key":"547_CR26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"547_CR27","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1189\/jlb.5BT1115-524R","volume":"100","author":"OO Oluwole","year":"2016","unstructured":"Oluwole, O. O. & Davila, M. L. At the bedside: clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies. J. Leukoc. Biol. 100, 1265\u20131272 (2016).","journal-title":"J. Leukoc. Biol."},{"key":"547_CR28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"547_CR29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018). This study reports the role of recipient macrophage-derived IL-1, IL-6 and NO in the pathogenesis of CRS in a mouse model.","journal-title":"Nat. Med."},{"key":"547_CR30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med."},{"key":"547_CR31","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah, N. N. et al. CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J. Clin. Oncol. 38, 1938\u20131950 (2020).","journal-title":"J. Clin. Oncol."},{"key":"547_CR32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009432","author":"JH Baird","year":"2020","unstructured":"Baird, J. H. et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood https:\/\/doi.org\/10.1182\/blood.2020009432 (2020).","journal-title":"Blood"},{"key":"547_CR33","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018). This study in humanized mice identifies the roles of monocyte-derived IL-1 and IL-6 as key cytokines mediating CRS and ICANS.","journal-title":"Nat. Med."},{"key":"547_CR34","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood.V100.2.654","volume":"100","author":"BA Nijmeijer","year":"2002","unstructured":"Nijmeijer, B. A., Willemze, R. & Falkenburg, J. H. F. An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD\/SCID mice. Blood 100, 654\u2013660 (2002).","journal-title":"Blood"},{"key":"547_CR35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"547_CR36","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1128\/IAI.68.3.1428-1434.2000","volume":"68","author":"M Nashleanas","year":"2000","unstructured":"Nashleanas, M. & Scott, P. Activated T cells induce macrophages to produce NO and control Leishmania major in the absence of tumor necrosis factor receptor p55. Infect. Immun. 68, 1428\u20131434 (2000).","journal-title":"Infect. Immun."},{"key":"547_CR37","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/ni1124","volume":"5","author":"C Orabona","year":"2004","unstructured":"Orabona, C. et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat. Immunol. 5, 1134\u20131142 (2004). This mouse study describes the crucial role of CD80- and CD86-mediated co-stimulation in T cell activation.","journal-title":"Nat. Immunol."},{"key":"547_CR38","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn, N. F. et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 35, 473\u2013488 (2019).","journal-title":"Cancer Cell"},{"key":"547_CR39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0196-9781(03)00083-4","volume":"24","author":"ME Anderson","year":"2003","unstructured":"Anderson, M. E. & Siahaan, T. J. Targeting ICAM-1\/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 24, 487\u2013501 (2003).","journal-title":"Peptides"},{"key":"547_CR40","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448\u2013457 (2015).","journal-title":"Nat. Immunol."},{"key":"547_CR41","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka, T. et al. IL-6 in inflammation, immunity and disease. Cold Spring Harb. Perspect. Biol. 6, a016295 (2014).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"547_CR42","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/j.celrep.2019.02.044","volume":"26","author":"D Mishra","year":"2019","unstructured":"Mishra, D. et al. Parabrachial interleukin-6 reduces body weight and food intake and increases thermogenesis to regulate energy metabolism. Cell Rep. 26, 3011\u20133026 (2019).","journal-title":"Cell Rep."},{"key":"547_CR43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","volume":"27","author":"CA Dinarello","year":"2009","unstructured":"Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Ann. Rev. Immunol. 27, 519\u2013550 (2009).","journal-title":"Ann. Rev. Immunol."},{"key":"547_CR44","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","volume":"31","author":"E Ricciotti","year":"2011","unstructured":"Ricciotti, E. & FitzGerald, G. A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 986\u20131000 (2011).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"547_CR45","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda, C., Dinarello, C. A. & Mantovani, A. The interleukin-1 family: back to the future. Immunity 39, 1003\u20131018 (2013).","journal-title":"Immunity"},{"key":"547_CR46","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720\u20133732 (2011).","journal-title":"Blood"},{"key":"547_CR47","doi-asserted-by":"crossref","first-page":"eaax7969","DOI":"10.1126\/sciimmunol.aax7969","volume":"5","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci. Immunol. 5, eaax7969 (2020).","journal-title":"Sci. Immunol."},{"key":"547_CR48","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","volume":"294","author":"M Sachdeva","year":"2019","unstructured":"Sachdeva, M., Duchateau, P., Depil, S., Poirot, L. & Valton, J. Granulocyte\u2013macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J. Biol. Chem. 294, 5430\u20135437 (2019).","journal-title":"J. Biol. Chem."},{"key":"547_CR49","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.immuni.2007.05.001","volume":"26","author":"MG Manz","year":"2007","unstructured":"Manz, M. G. Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity 26, 537\u2013541 (2007).","journal-title":"Immunity"},{"key":"547_CR50","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner, R. M. et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133, 697\u2013709 (2019).","journal-title":"Blood"},{"key":"547_CR51","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/312724a0","volume":"312","author":"D Pennica","year":"1984","unstructured":"Pennica, D. et al. Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312, 724\u2013729 (1984).","journal-title":"Nature"},{"key":"547_CR52","doi-asserted-by":"crossref","first-page":"eaax8861","DOI":"10.1126\/scitranslmed.aax8861","volume":"11","author":"J Li","year":"2019","unstructured":"Li, J. et al. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Sci. Transl. Med. 11, eaax8861 (2019).","journal-title":"Sci. Transl. Med."},{"key":"547_CR53","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jcb.21868","volume":"105","author":"CF Lin","year":"2008","unstructured":"Lin, C. F. et al. IFN-\u03b3 synergizes with LPS to induce nitric oxide biosynthesis through glycogen synthase kinase-3-inhibited IL-10. J. Cell. Biochem. 105, 746\u2013755 (2008).","journal-title":"J. Cell. Biochem."},{"key":"547_CR54","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.4049\/jimmunol.176.8.4804","volume":"176","author":"S T\u00f6temeyer","year":"2006","unstructured":"T\u00f6temeyer, S. et al. IFN-\u03b3 enhances production of nitric oxide from macrophages via a mechanism that depends on nucleotide oligomerization domain-2. J. Immunol. 176, 4804\u20134810 (2006).","journal-title":"J. Immunol."},{"key":"547_CR55","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bbamem.2008.08.027","volume":"1788","author":"CT Capaldo","year":"2009","unstructured":"Capaldo, C. T. & Nusrat, A. Cytokine regulation of tight junctions. Biochim. Biophys. Acta. 1788, 864\u2013871 (2009).","journal-title":"Biochim. Biophys. Acta."},{"key":"547_CR56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbrc.2018.11.021","volume":"507","author":"MT Rahman","year":"2018","unstructured":"Rahman, M. T. et al. IFN-\u03b3, IL-17A, or zonulin rapidly increase the permeability of the blood\u2013brain and small intestinal epithelial barriers: relevance for neuro-inflammatory diseases. Biochem. Biophys. Res. Commun. 507, 274\u2013279 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"547_CR57","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1128\/JVI.03149-13","volume":"88","author":"Q Chai","year":"2014","unstructured":"Chai, Q., He, W. Q., Zhou, M., Lu, H. & Fu, Z. F. Enhancement of blood\u2013brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines\/cytokines induced by rabies virus infection. J. Virol. 88, 4698\u20134710 (2014).","journal-title":"J. Virol."},{"key":"547_CR58","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.4049\/jimmunol.1103460","volume":"189","author":"MA Lopez-Ramirez","year":"2012","unstructured":"Lopez-Ramirez, M. A. et al. Role of caspases in cytokine-induced barrier breakdown in human brain endothelial cells. J. Immunol. 189, 3130\u20133139 (2012).","journal-title":"J. Immunol."},{"key":"547_CR59","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.peptides.2004.08.034","volume":"26","author":"AM Volmar","year":"2005","unstructured":"Volmar, A. M. The role of atrial natriuretic peptide in the immune system. Peptides 26, 1086\u20131094 (2005).","journal-title":"Peptides"},{"key":"547_CR60","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","volume":"564","author":"V Staedtke","year":"2018","unstructured":"Staedtke, V. et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564, 273\u2013277 (2018).","journal-title":"Nature"},{"key":"547_CR61","volume":"8","author":"ML Davila","year":"2013","unstructured":"Davila, M. L., Kloss, C. C., Gunset, G. & Sadelain, M. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS ONE 8, e61338 (2013).","journal-title":"PLoS ONE"},{"key":"547_CR62","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2005-09-3716","volume":"107","author":"A Bondanza","year":"2006","unstructured":"Bondanza, A. et al. Suicide gene therapy of graft versus-host disease induced by central memory human T lymphocytes. Blood 107, 1828\u20131836 (2006).","journal-title":"Blood"},{"key":"547_CR63","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2016-08-732636","volume":"130","author":"S Mastaglio","year":"2017","unstructured":"Mastaglio, S. et al. NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus host disease. Blood 130, 606\u2013618 (2017).","journal-title":"Blood"},{"key":"547_CR64","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1089\/hum.2017.243","volume":"29","author":"EL Siegler","year":"2018","unstructured":"Siegler, E. L. & Wang, P. Preclinical models in chimeric antigen receptor engineered T-cell therapy. Hum. Gene Ther. 29, 534\u2013546 (2018).","journal-title":"Hum. Gene Ther."},{"key":"547_CR65","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","volume":"130","author":"FL Locke","year":"2017","unstructured":"Locke, F. L. et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-hodgkin lymphoma (NHL). Blood 130, 1547 (2017).","journal-title":"Blood"},{"key":"547_CR66","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1097\/CCM.0b013e3181922bd3","volume":"37","author":"A Dyson","year":"2009","unstructured":"Dyson, A. & Singer, M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit. Care Med. 37, S30\u2013S37 (2009).","journal-title":"Crit. Care Med."},{"key":"547_CR67","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4161\/viru.24530","volume":"4","author":"AV Page","year":"2013","unstructured":"Page, A. V. & Liles, W. C. Biomarkers of endothelial activation\/dysfunction in infectious diseases. Virulence 4, 507\u2013516 (2013).","journal-title":"Virulence"},{"key":"547_CR68","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1160\/TH14-09-0731","volume":"113","author":"M Schwameis","year":"2015","unstructured":"Schwameis, M., Sch\u00f6rgenhofer, C., Assinger, A., Steiner, M. M. & Jilma, B. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb. Haemost. 113, 708\u2013718 (2015).","journal-title":"Thromb. Haemost."},{"key":"547_CR69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","volume":"86","author":"J Gust","year":"2019","unstructured":"Gust, J. et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann. Neurol. 86, 42\u201354 (2019).","journal-title":"Ann. Neurol."},{"key":"547_CR70","volume":"3","author":"HJ Kim","year":"2018","unstructured":"Kim, H. J., Tsao, J. W. & Stanfill, A. G. The current state of biomarkers of mild traumatic brain injury. JCI Insight 3, e97105 (2018).","journal-title":"JCI Insight"},{"key":"547_CR71","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1073858413504466","volume":"20","author":"MV Sofroniew","year":"2014","unstructured":"Sofroniew, M. V. Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. Neuroscientist 20, 160\u2013172 (2014).","journal-title":"Neuroscientist"},{"key":"547_CR72","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"547_CR73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-5728(94)90005-1","volume":"55","author":"EG Gutierrez","year":"1994","unstructured":"Gutierrez, E. G., Banks, W. A. & Kastin, A. J. Blood-borne interleukin-1 receptor antagonist crosses the blood\u2013brain barrier. J. Neuroimmunol. 55, 153\u2013160 (1994).","journal-title":"J. Neuroimmunol."},{"key":"547_CR74","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/jcbfm.2010.103","volume":"31","author":"J Galea","year":"2011","unstructured":"Galea, J. et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J. Cereb. Blood Flow. Metab. 31, 439\u2013447 (2011).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"547_CR75","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126\u2013142.e17 (2020).","journal-title":"Cell"},{"key":"547_CR76","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ajpath.2011.01.016","volume":"178","author":"K Dorovini-Zis","year":"2011","unstructured":"Dorovini-Zis, K. et al. The neuropathology of fatal cerebral malaria in Malawian children. Am. J. Pathol. 178, 2146\u20132158 (2011).","journal-title":"Am. J. Pathol."},{"key":"547_CR77","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1038\/s41467-020-19737-2","volume":"11","author":"M Olah","year":"2020","unstructured":"Olah, M. et al. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer\u2019s disease. Nat. Commun. 11, 6129 (2020).","journal-title":"Nat. Commun."},{"key":"547_CR78","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1126\/science.1202529","volume":"333","author":"RC Paolicelli","year":"2011","unstructured":"Paolicelli, R. C. et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456\u20131458 (2011).","journal-title":"Science"},{"key":"547_CR79","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.celrep.2017.07.004","volume":"20","author":"P Reu","year":"2017","unstructured":"Reu, P. et al. The lifespan and turnover of microglia in the human brain. Cell Rep. 20, 779\u2013784 (2017).","journal-title":"Cell Rep."},{"key":"547_CR80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41586-019-1088-4","volume":"568","author":"JV Pluvinage","year":"2019","unstructured":"Pluvinage, J. V. et al. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature 568, 187\u2013192 (2019).","journal-title":"Nature"},{"key":"547_CR81","unstructured":"DeAngelo, D. J. et al. Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study) [abstract P217]. SITC 2017 Annual Meeting Abstracts Book https:\/\/higherlogicdownload.s3.amazonaws.com\/SITCANCER\/3bcb5ebf-803a-42fe-83b6-0773bc4eb962\/UploadedImages\/Annual%20Meeting%202017\/SITC_2017_Abstract_Book.pdf (2017)."},{"key":"547_CR82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","volume":"16","author":"KM Mahadeo","year":"2019","unstructured":"Mahadeo, K. M. et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat. Rev. Clin. Oncol. 16, 45\u201363 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"547_CR83","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"547_CR84","volume":"8","author":"MV Maus","year":"2020","unstructured":"Maus, M. V. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J. Immunother. Cancer 8, e001511 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"547_CR85","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto, N. et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959\u20133964 (2008).","journal-title":"Blood"},{"key":"547_CR86","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil, L. J. et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J. Clin. Oncol. 38, 3119\u20133128 (2020).","journal-title":"J. Clin. Oncol."},{"key":"547_CR87","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2020.38.15_suppl.8011","volume":"38","author":"P Strati","year":"2020","unstructured":"Strati, P. et al. Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel). J. Clin. Oncol. 38, 8011 (2020).","journal-title":"J. Clin. Oncol."},{"key":"547_CR88","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2019-126081","volume":"134","author":"MV Topp","year":"2019","unstructured":"Topp, M. V. et al. Earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory large B cell lymphoma. Blood 134, 243 (2019).","journal-title":"Blood"},{"key":"547_CR89","first-page":"193","volume":"130","author":"T Siddiqi","year":"2017","unstructured":"Siddiqi, T. et al. Patient characteristics and pre-infusion biomarkers of inflammation correlate with clinical outcomes after treatment with the defined composition, CD19-targeted CAR T cell product, JCAR017. Blood 130, 193 (2017).","journal-title":"Blood"},{"key":"547_CR90","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson, C. A. et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J. Clin. Oncol. 38, 3095\u20133106 (2020).","journal-title":"J. Clin. Oncol."},{"key":"547_CR91","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"547_CR92","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).","journal-title":"Sci. Transl. Med."},{"key":"547_CR93","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle, C. J. et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J. Clin. Oncol. 35, 3010\u20133020 (2017).","journal-title":"J. Clin. Oncol."},{"key":"547_CR94","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama, A. V. et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 133, 1876\u20131887 (2019).","journal-title":"Blood"},{"key":"547_CR95","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer, J. N. et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J. Clin. Oncol. 35, 1803\u20131813 (2017).","journal-title":"J. Clin. Oncol."},{"key":"547_CR96","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","volume":"133","author":"SS Neelapu","year":"2019","unstructured":"Neelapu, S. S. CAR-T efficacy: is conditioning the key? Blood 133, 1799\u20131800 (2019).","journal-title":"Blood"},{"key":"547_CR97","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","volume":"135","author":"SS Neelapu","year":"2020","unstructured":"Neelapu, S. S. et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 135, 2106\u20132109 (2020).","journal-title":"Blood"},{"key":"547_CR98","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying, Z. et al. A safe and potent anti-CD19 CAR T cell therapy. Nat. Med. 25, 947\u2013953 (2019). This study reports a novel CD19CAR construct with 4-1BB and CD3\u03b6 co-stimulatory domains that in clinical practice conferred protection against B cell lymphomas without increasing serum cytokine levels or inducing CRS.","journal-title":"Nat. Med."},{"key":"547_CR99","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019). This study reports a modified CD19CAR construct with lower binding affinity, resulting in both reduced CRS and increased expansion of CAR T cell populations in vivo.","journal-title":"Nat. Med."},{"key":"547_CR100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicenter, phase 1-2 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"547_CR101","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","volume":"26","author":"JN Brudno","year":"2020","unstructured":"Brudno, J. N. et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat. Med. 26, 270\u2013280 (2020).","journal-title":"Nat. Med."},{"key":"547_CR102","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"547_CR103","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019). This study shows that altering the activation potential of a CAR construct can influence T cell differentiation and the balance between effector and memory T cell phenotypes.","journal-title":"Nat. Med."},{"key":"547_CR104","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","volume":"12","author":"UH Acharya","year":"2019","unstructured":"Acharya, U. H. et al. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Exp. Rev. Hematol. 12, 195\u2013205 (2019).","journal-title":"Exp. Rev. Hematol."},{"key":"547_CR105","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","volume":"26","author":"E Huarte","year":"2020","unstructured":"Huarte, E. et al. Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy. Clin. Cancer Res. 26, 6299\u20136309 (2020).","journal-title":"Clin. Cancer Res."},{"key":"547_CR106","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky, J. A. et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a TH1-selective pressure in T lymphocytes. Blood 122, 2539\u20132549 (2013).","journal-title":"Blood"},{"key":"547_CR107","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2016.262","volume":"31","author":"M Ruella","year":"2017","unstructured":"Ruella, M. et al. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia 31, 246\u2013248 (2017).","journal-title":"Leukemia"},{"key":"547_CR108","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","volume":"11","author":"K Mestermann","year":"2019","unstructured":"Mestermann, K. et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci. Transl. Med. 11, eaau5907 (2019).","journal-title":"Sci. Transl. Med."},{"key":"547_CR109","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ccell.2019.12.014","volume":"37","author":"C Sun","year":"2020","unstructured":"Sun, C. et al. THEMIS-SHP1 recruitment by 4-1BB tunes LCK-mediated priming of chimeric antigen receptor-redirected T cells. Cancer Cell 37, 216\u2013225.e6 (2020).","journal-title":"Cancer Cell"},{"key":"547_CR110","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","volume":"4","author":"P Strati","year":"2020","unstructured":"Strati, P. et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 4, 3123\u20133127 (2020).","journal-title":"Blood Adv."},{"key":"547_CR111","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1056\/NEJMc2020754","volume":"383","author":"JI Henter","year":"2020","unstructured":"Henter, J. I. et al. Emapalumab in primary hemophagocytic lymphohistiocytosis. N. Engl. J. Med. 383, 596\u2013598 (2020).","journal-title":"N. Engl. J. Med."},{"key":"547_CR112","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/ajt.14185","volume":"17","author":"DA Boardman","year":"2017","unstructured":"Boardman, D. A. et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am. J. Transplant. 17, 931\u2013943 (2017).","journal-title":"Am. J. Transplant."},{"key":"547_CR113","volume":"5","author":"AC Boroughs","year":"2019","unstructured":"Boroughs, A. C. et al. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight 5, e126194 (2019).","journal-title":"JCI Insight"},{"key":"547_CR114","doi-asserted-by":"crossref","first-page":"eaaz3866","DOI":"10.1126\/scitranslmed.aaz3866","volume":"12","author":"NAJ Dawson","year":"2020","unstructured":"Dawson, N. A. J. et al. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells. Sci. Transl. Med. 12, eaaz3866 (2020).","journal-title":"Sci. Transl. Med."},{"key":"547_CR115","doi-asserted-by":"crossref","first-page":"104220","DOI":"10.1016\/j.cellimm.2020.104220","volume":"358","author":"I Rosado-S\u00e1nchez","year":"2020","unstructured":"Rosado-S\u00e1nchez, I. & Levings, M. K. Building a CAR-Treg: going from the basic to the luxury model. Cell. Immunol. 358, 104220 (2020).","journal-title":"Cell. Immunol."},{"key":"547_CR116","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.clml.2020.04.020","volume":"20","author":"SS Jatiani","year":"2020","unstructured":"Jatiani, S. S. et al. Myeloma CAR-T CRS management with IL-1R antagonist anakinra. Clin. Lymphoma Myeloma Leuk. 20, 632\u2013636.e1 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"547_CR117","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nri3839","volume":"15","author":"I Voskoboinik","year":"2015","unstructured":"Voskoboinik, I. et al. Perforin and granzymes: function, dysfunction and human pathology. Nat. Rev. Immunol. 15, 388\u2013400 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"547_CR118","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom, A. A., Horne, A. & De Benedetti, F. Macrophage activation syndrome in the era of biologic therapy. Nat. Rev. Rheumatol. 12, 259\u2013268 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"547_CR119","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/bloodadvances.2020001605","volume":"4","author":"V Gadoury-Levesque","year":"2020","unstructured":"Gadoury-Levesque, V. et al. Frequency and spectrum of disease-causing variants in 1892 patients with suspected genetic HLH disorders. Blood Adv. 4, 2578\u20132594 (2020).","journal-title":"Blood Adv."},{"key":"547_CR120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","volume":"15","author":"DT Teachey","year":"2018","unstructured":"Teachey, D. T. et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u2018ALL\u2019. Nat. Rev. Clin. Oncol. 15, 218 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"547_CR121","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey, D. T. et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121, 5154\u20135157 (2013).","journal-title":"Blood"},{"key":"547_CR122","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1172\/JCI130059","volume":"130","author":"K Ishii","year":"2020","unstructured":"Ishii, K. et al. Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. J. Clin. Invest. 130, 5425\u20135443 (2020).","journal-title":"J. Clin. Invest."},{"key":"547_CR123","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1182\/blood-2010-08-300046","volume":"117","author":"J Sumegi","year":"2011","unstructured":"Sumegi, J. et al. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood 117, e151\u2013e160 (2011).","journal-title":"Blood"},{"key":"547_CR124","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ng.3089","volume":"46","author":"SW Canna","year":"2014","unstructured":"Canna, S. W. et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat. Genet. 46, 1140\u20131146 (2014).","journal-title":"Nat. Genet."},{"key":"547_CR125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore, J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. Science 368, 473\u2013474 (2020).","journal-title":"Science"},{"key":"547_CR126","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","volume":"46","author":"Q Ruan","year":"2020","unstructured":"Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46, 846\u2013848 (2020).","journal-title":"Intensive Care Med."},{"key":"547_CR127","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620\u20132629 (2020).","journal-title":"J. Clin. Invest."},{"key":"547_CR128","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","volume":"2","author":"G Guaraldi","year":"2020","unstructured":"Guaraldi, G. et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2, e474\u2013e484 (2020).","journal-title":"Lancet Rheumatol."},{"key":"547_CR129","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl Acad. Sci. USA 117, 10970\u201310975 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"547_CR130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.021","volume":"76","author":"C Campochiaro","year":"2020","unstructured":"Campochiaro, C. et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-center retrospective cohort study. Eur. J. Intern. Med. 76, 43\u201349 (2020).","journal-title":"Eur. J. Intern. Med."},{"key":"547_CR131","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama, C. et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. N. Engl. J. Med. 384, 20\u201330 (2021).","journal-title":"N. Engl. J. Med."},{"key":"547_CR132","doi-asserted-by":"crossref","first-page":"100418","DOI":"10.1016\/j.eclinm.2020.100418","volume":"24","author":"T Kewan","year":"2020","unstructured":"Kewan, T. et al. Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study. EClinicalMedicine 24, 100418 (2020).","journal-title":"EClinicalMedicine"},{"key":"547_CR133","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","volume":"2","author":"T Huet","year":"2020","unstructured":"Huet, T. et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2, e393\u2013e400 (2020).","journal-title":"Lancet Rheumatol."},{"key":"547_CR134","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","volume":"2","author":"G Cavalli","year":"2020","unstructured":"Cavalli, G. et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2, e325\u2013e331 (2020).","journal-title":"Lancet Rheumatol."},{"key":"547_CR135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jaci.2020.11.006","volume":"147","author":"G Bozzi","year":"2021","unstructured":"Bozzi, G. et al. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study. J. Allergy Clin. Immunol. 147, 561\u2013566.e4 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"547_CR136","doi-asserted-by":"crossref","first-page":"18951","DOI":"10.1073\/pnas.2009017117","volume":"117","author":"R Cauchois","year":"2020","unstructured":"Cauchois, R. et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc. Natl Acad. Sci. USA 117, 18951\u201318953 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"547_CR137","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127\u2013132 (2020).","journal-title":"Nature"},{"key":"547_CR138","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10555-010-9229-0","volume":"29","author":"CA Dinarello","year":"2010","unstructured":"Dinarello, C. A. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 29, 317\u2013329 (2010).","journal-title":"Cancer Metastasis Rev."},{"key":"547_CR139","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1073\/pnas.0437939100","volume":"100","author":"E Voronov","year":"2003","unstructured":"Voronov, E. et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl Acad. Sci. USA 100, 2645\u20132650 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"547_CR140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","volume":"23","author":"N Horikawa","year":"2017","unstructured":"Horikawa, N. et al. Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin. Cancer Res. 23, 587\u2013599 (2017).","journal-title":"Clin. Cancer Res."},{"key":"547_CR141","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fphys.2014.00114","volume":"5","author":"E Voronov","year":"2014","unstructured":"Voronov, E., Yaron, C. & Apte, R. N. The role IL-1 in tumor-mediated angiogenesis. Front. Physiol. 5, 114 (2014).","journal-title":"Front. Physiol."},{"key":"547_CR142","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1073\/pnas.1812266115","volume":"116","author":"I Kaplanov","year":"2019","unstructured":"Kaplanov, I. et al. Blocking IL-1\u03b2 reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc. Natl Acad. Sci. USA 116, 1361\u20131369 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"547_CR143","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey, A. et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 18, 3204\u20133218 (2017).","journal-title":"Cell Rep."},{"key":"547_CR144","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Anti-inflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"547_CR145","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833\u20131842 (2017).","journal-title":"Lancet"},{"key":"547_CR146","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40487-018-0089-z","volume":"6","author":"A Litmanovich","year":"2018","unstructured":"Litmanovich, A., Khazim, K. & Cohen, I. The role of interleukin-1 in the pathogenesis of cancer and its potential as a therapeutic target in clinical practice. Oncol. Ther. 6, 109\u2013127 (2018).","journal-title":"Oncol. Ther."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00547-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00547-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00547-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:02:04Z","timestamp":1733940124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-021-00547-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":146,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["547"],"URL":"https:\/\/doi.org\/10.1038\/s41577-021-00547-6","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"1 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S. and T.G. are listed as inventors in a Memorial Sloan Kettering-held patent application related to treatment of cytokine release syndrome: \u2018Methods and compositions for alleviating cytokine release syndrome\u2019 (WO2019099993A1). E.C.M. is scientific co-founder of Quell Therapeutics Ltd, which is developing chimeric antigen receptor (CAR)-modified regulatory T cells, and has served as a consultant to Kite, a Gilead company. S.S.N. served as consultant to Kite, a Gilead Company, Merck, Bristol-Myers Squibb, Novartis, Celgene, Pfizer, Allogene Therapeutics, Cell Medica\/Kuur, Incyte, Precision Biosciences, Legend Biotech, Adicet Bio, Calibr and Unum Therapeutics; received research support from Kite, a Gilead Company, Bristol-Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene Therapeutics, Precision Biosciences and Acerta; received royalties from Takeda Pharmaceuticals; and has intellectual property related to cell therapy.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}